Stewart Greg L, Sage Adam P, Enfield Katey S S, Marshall Erin A, Cohn David E, Lam Wan L
Department of Integrative Oncology, BC Cancer Research Centre, Vancouver, BC, Canada.
Front Genet. 2021 Jan 11;11:615378. doi: 10.3389/fgene.2020.615378. eCollection 2020.
Long non-coding RNAs (lncRNAs) have long been implicated in cancer-associated phenotypes. Recently, a class of lncRNAs, known as -acting, have been shown to regulate the expression of neighboring protein-coding genes and may represent undiscovered therapeutic action points. The chromatin architecture modification gene has recently been described to be aberrantly expressed in lung adenocarcinoma (LUAD). However, the mechanisms mediating the expression of in LUAD remain unknown. Here we investigate the deregulation of a putative -acting lncRNA in LUAD, and its effect on the oncogene .
LncRNA expression was determined from RNA-sequencing data of tumor and matched non-malignant tissues from 36 LUAD patients. Transcripts with significantly deregulated expression were identified and validated in a secondary LUAD RNA-seq dataset (TCGA). SiRNA-mediated knockdown of a candidate -acting lncRNA was performed in BEAS-2B cells. Quantitative real-time PCR was used to observe the effects of lncRNA knockdown on the expression of HMGA1.
We identified the lncRNA RP11.513I15.6, which we refer to as HMGA1-, neighboring to be significantly downregulated in both LUAD cohorts. Conversely, we found significantly overexpressed in LUAD and anticorrelated with HMGA1-. experiments demonstrated siRNA-mediated inhibition of HMGA1- in immortalized non-malignant lung epithelial cells resulted in a significant increase in gene expression.
Our results suggest that HMGA1- is a novel -acting lncRNA that negatively regulates gene expression in lung cells. Further characterization of this regulatory mechanism may advance our understanding of the maintenance of lung cancer phenotypes and uncover a novel therapeutic intervention point for tumors driven by .
长期以来,长链非编码RNA(lncRNAs)一直与癌症相关表型有关。最近,一类被称为顺式作用的lncRNAs已被证明可调节相邻蛋白质编码基因的表达,可能代表未被发现的治疗作用靶点。染色质结构修饰基因最近被描述在肺腺癌(LUAD)中异常表达。然而,介导LUAD中该基因表达的机制仍不清楚。在这里,我们研究了LUAD中一种假定的顺式作用lncRNA的失调及其对癌基因的影响。
从36例LUAD患者的肿瘤及配对的非恶性组织的RNA测序数据中确定lncRNA表达。在第二个LUAD RNA-seq数据集(TCGA)中鉴定并验证表达显著失调的转录本。在BEAS-2B细胞中进行小干扰RNA(siRNA)介导的候选顺式作用lncRNA敲低。使用定量实时PCR观察lncRNA敲低对HMGA1表达的影响。
我们鉴定出lncRNA RP11.513I15.6,我们将其称为HMGA1-AS1,其在两个LUAD队列中均与HMGA1相邻且显著下调。相反,我们发现HMGA1在LUAD中显著过表达且与HMGA1-AS1呈负相关。实验表明,在永生化非恶性肺上皮细胞中,siRNA介导的HMGA1-AS1抑制导致HMGA1基因表达显著增加。
我们的结果表明,HMGA1-AS1是一种新型的顺式作用lncRNA,可在肺细胞中负调节HMGA基因表达。对这种调节机制的进一步表征可能会加深我们对肺癌表型维持的理解,并揭示由HMGA驱动的肿瘤的新型治疗干预点。